Open-Label Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-Steroidal Anti-Inflammatory Drug Treatment.

Trial Profile

Open-Label Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-Steroidal Anti-Inflammatory Drug Treatment.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2014

At a glance

  • Drugs Ibuprofen/famotidine (Primary)
  • Indications Back pain; NSAID-induced gastrointestinal damage; Osteoarthritis; Pain; Rheumatoid arthritis
  • Focus Adverse reactions; Registrational
  • Sponsors Horizon Pharma
  • Most Recent Events

    • 24 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jul 2010 Planned end date changed from 1 Mar 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 16 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top